Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations

BACKGROUND: The approval of vemurafenib in the US 2011 and in Europe 2012 improved the therapy of not resectable or metastatic melanoma. Patients carrying a substitution of valine to glutamic acid at codon 600 (p.V600E) or a substitution of valine to leucine (p.V600K) in BRAF show complete or partia...

Descripción completa

Detalles Bibliográficos
Autores principales: Ihle, Michaela Angelika, Fassunke, Jana, König, Katharina, Grünewald, Inga, Schlaak, Max, Kreuzberg, Nicole, Tietze, Lothar, Schildhaus, Hans-Ulrich, Büttner, Reinhard, Merkelbach-Bruse, Sabine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893431/
https://www.ncbi.nlm.nih.gov/pubmed/24410877
http://dx.doi.org/10.1186/1471-2407-14-13

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893431/
https://www.ncbi.nlm.nih.gov/pubmed/24410877
http://dx.doi.org/10.1186/1471-2407-14-13

Ejemplares similares